Seal Rock Therapeutics Receives Small Business Innovation Research Grant from National Institutes of Health to Support Novel Therapy for Acute Alcoholic Hepatitis

March 29, 2023, Seattle, WA – Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has been awarded a $358,000 grant from the National Institutes of Health Department of Health and Human Services, National Institute on Alcohol Abuse and Alcoholism to support evaluation of SRT-015, a next-generation, liver-selective inhibitor of Apoptosis Signal-reducing Kinase 1 (ASK1)  as a treatment for acute alcoholic hepatitis.
‍
“We appreciate this award to support further evaluation of SRT-015 for alcoholic hepatitis,” said Neil McDonnell, CEO of Seal Rock. “Our preclinical and clinical data to date have demonstrated that SRT-015 is well differentiated and support its further advancement into the clinic.”
‍
This support is provided under award number R43AA029931.
‍
‍About SRT-015
SRT-015 is a next generation inhibitor of ASK1 developed internally by Seal Rock Therapeutics. Optimized to overcome the liabilities of selonsertib, and with a liver-preferential distribution, SRT-015 is positioned as a first-in-class product candidate for NASH and AH.

‍About Seal Rock Therapeutics​
‍Seal Rock Therapeutics is a privately held, clinical stage company based in Seattle focused on developing first-in-class and best-in-class treatments for severe diseases with limited or no available therapies. Seal Rock is led by an experienced management team with a track record of successful drug discovery, development and commercialization. The company’s clinical-stage lead product candidate, SRT-015, is a highly optimized, first-in-class ASK1 inhibitor.  Seal Rock is also developing preclinical-stage brain-penetrant ASK1/LRRK2 dual kinase inhibitors for treatment of neurodegenerative conditions such as Parkinson’s disease and ALS.
‍
For more information, please visit www.sealrocktx.com

Media Contact
‍Julie Rathbun
Rathbun Communications
‍Julie@rathbuncomm.com
‍206-769-9219